Shots: Tum Bio to receive $1M upfront, up to $73M milestones and royalties on sales. Chiesi to get worldwide development and commercialization rights & will be responsible for its clinical trials The focus of the agreement is to develop and commercialize NCE401, a TGF-beta inhibitor in the fields of respiratory diseases NCE401 is a preclinical […]Read More
Tags : Chiesi Farmaceutici
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US